200例肺腺癌脑转移患者驱动基因突变情况及预后关系  

Driver Genes Mutation and Survival Analysis in 200 Patients with Pulmonary Adenocarcinoma Brain Metastasis

作　　者：朱中山[1] 严文辉[1] 李小兵[1] 杨洲[1] 白鹏[2] ZHU Zhong-shan;YAN Wen-hui;LI Xiao-bing;YANG Zhou;BAI Peng(Dept.of Oncology,The 2nd People＇s Hospital of Hunan,Changsha Hunan 410007;Dept.ofMinimally Invisive Neurosurgery,The 1st Affiliated Hospital of Kunming Medical University,Kunming Yunnan650032,China)

机构地区：[1]湖南省第二人民医院肿瘤科,湖南长沙410007 [2]昆明医科大学第一附属医院神经微创外科,云南昆明650032

出　　处：《昆明医科大学学报》2018年第8期47-50,共4页Journal of Kunming Medical University

基　　金：湖南省卫计委科研计划基金资助项目(B2013087)

摘　　要：目的探讨肺腺癌脑转移患者驱动基因突变情况及预后关系.方法选取湖南省第二人民院2013年1月至2015年12月来就诊经病理确诊为肺腺癌脑转移患者200例,检测EGFR、KRAS、ALK、Her-2的基因突变情况,分析EGFR基因突变与患者临床病理及预后的关系.结果 EGFR、KRAS、ALK、Her-2的基因突变率分别为48.5%、5.5%、6.5%、3.5%.EGFR基因突变在性别、年龄、BMI、分化程度等方面比较,差异有统计学意义(P<0.05);而在吸烟方面比较,差异无统计学意义(P>0.05).EGFR基因突变接受靶向治疗的患者生存时间长于未接受靶向治疗的患者(28.0±4.5)月vs(11.2±1.4)月;经Log Rank(Mantel-Cox)统计学分析,2组中位生存时间差异有统计学意义(P<0.05).结论肺腺癌脑转移患者驱动基因EGFR突变有较高的突变率,应用靶向治疗可明显延长生存时间.Objective To investigate the relationship between the driver genes mutation and the survival in patients with pulmonary adenocarcinoma brain metastasis. Methods We enrolled 200 patients with pulmonary adenocarcinoma brain metastasis confirmed histologically from Jan 2013 to Dec 2015, and tested EGFR,KRAS, ALK, Her-2 gene mutation, analyzed the relationship between EGFR gene mutation and clinicopathological data and prognosis of the patients.Results The mutation rates of EGFR, KRAS, ALK and Her-2 gene mutation were 48.5%, 5.5%, 6.5%, 3.5%, respectively. Compared with EGFR gene mutation patients, the sex, age, BMI, differentiation were significant different（P 〈0.05）, however, the smoking was not significant different（P 〈0.05）. Patients with EGFR gene mutation who received targeted therapy survived longer than who did not receive targeted therapy,（28.0 ±4.5）months vs（11.2 ±1.4）months. By Log Rank（Mantel-Cox）, the median survival time between the two groups was statistically significant（P 〈0.05）.Conclusions The mutation rate of EGFR gene mutation was high in patients with pulmonary adenocarcinoma brain metastasis, and the patients will survivel longer by targeted therapy.

关 键 词：肺腺癌 脑转移 靶向治疗 驱动基因 

分 类 号：R734[医药卫生—肿瘤]